NCT07027046 Application of da Vinci SP for Endometrial Cancer Surgical Staging
| NCT ID | NCT07027046 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute, Naples |
| Condition | Endometrial Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 564 participants |
| Start Date | 2025-04-03 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 564 participants in total. It began in 2025-04-03 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective Multicenter Observational Study The study involves the consecutive inclusion of every patient with endometrial cancer undergoing staging surgical treatment using a robotic approach with the da Vinci SP platform.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed endometrial carcinoma (including uterine carcinosarcoma) * Performance status (ECOG) 0 - 1 * Patients undergoing staging surgery for endometrial cancer, including but not limited to robotic hysterectomy with bilateral salpingo-oophorectomy (ovarian preservation in selected patients is not an exclusion criterion) and possible sentinel lymph node biopsy/pelvic ± para-aortic lymphadenectomy * Signed informed consent to participate in the study Exclusion Criteria: * Patients scheduled for an additional extra-genital surgical procedure during the staging surgery for endometrial carcinoma * Patients with anesthesiological contraindications to a minimally invasive approach * Synchronous tumor * Recurrence of endometrial carcinoma * Dementia or significantly altered mental status that may impair understanding and the ability to provide informed consent * Any reason that may interfere with regular follow-up, even if limited to the first 30 days post-surgery
Contact & Investigator
Vito Chiantera, MD
PRINCIPAL INVESTIGATOR
IRCCS I.N.T. "G. Pascale"
Frequently Asked Questions
Who can join the NCT07027046 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Endometrial Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07027046 currently recruiting?
Yes, NCT07027046 is actively recruiting participants. Contact the research team at giuseppe.cucinella@istitutotumori.na.it for enrollment information.
Where is the NCT07027046 trial being conducted?
This trial is being conducted at Naples, Italy, Milan, Italy, Roma, Italy.
Who is sponsoring the NCT07027046 clinical trial?
NCT07027046 is sponsored by National Cancer Institute, Naples. The principal investigator is Vito Chiantera, MD at IRCCS I.N.T. "G. Pascale". The trial plans to enroll 564 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.